UCB and Ra Pharmaceuticals (RARX) merger information including expected completion date and offer price are displayed in the deal information table below.
This deal was successfully consummated on April 1, 2020
| Merger Details | Value |
|---|---|
| Acquisition Target Stock Name | Ra Pharmaceuticals |
| Acquisition Target Stock Ticker | RARX |
| Acquirer Stock Name | UCB |
| Announcement Date | October 10, 2019 |
| Expected Completion Date | March 31, 2020 |
| Offer Price | $48.00 |
| Payment Method | All Cash Deal |
| Actual Completion Date | April 1, 2020 |
The major Ra Pharmaceuticals (RARX) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the UCB takeover of Ra Pharmaceuticals (RARX) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on the Ra Pharmaceuticals (RARX) buyout, follow this link Ra Pharmaceuticals (RARX). Change the ticker symbol as required to access news and acquisition details of additional merger stocks. The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated RARX news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deals by simply entering a ticker symbol into the search box in the menu bar above or click on an acquisition target stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Ra Pharmaceuticals (NASDAQ: RARX) Merger - Acquisition News and Events
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment.
The company’s pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
